Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non‐small‐cell lung cancer cell lines

MET targeted therapies are under clinical evaluation for non‐small‐cell lung cancer (NSCLC) patients. Tyrosine kinase inhibitors (TKI) against MET have varying degrees of specificity. Tivantinib (ARQ 197) is reported to be a non‐ATP competitive selective MET inhibitor. We aimed to compare the activi...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Mol Oncol
मुख्य लेखकों: Calles, Antonio, Kwiatkowski, Nicholas, Cammarata, Bernard K., Ercan, Dalia, Gray, Nathanael S., Jänne, Pasi A.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: John Wiley and Sons Inc. 2014
विषय:
Research Articles
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528687/
https://ncbi.nlm.nih.gov/pubmed/25226813
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2014.08.011
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन